Bilastine in higher doses in chronic spontaneous urticaria

---

Short Communication

Author Details : Kiran Godse*, Gauri Godse

Volume : 5, Issue : 3, Year : 2019

Article Page : 261-263

https://doi.org/10.18231/j.ijced.2019.056

Suggest article by email

Get Permission

---

Abstract

Objective: To evaluate efficacy and safety of bilastine in higher than usual doses in patients with chronic
spontaneous urticaria (CSU).
Material and Methods: Adult patients with CSU with pruritus and wheal score of more than two
were investigated for complete blood count, urine examination, blood sugar level and thyroid-stimulating
hormone level and treated with bilastine 20 mg (one tablet) before breakfast. In patients who did not show
satisfactory response, dose was increased to 40 mg (two tablets) before breakfast at the end of one week
and 80 mg (two divided doses) at the end of two weeks, if no response seen after the end of one week.
Symptoms were evaluated using urticaria activity score (UAS) and sedation score.
Results: A total of 30 patients (mean age 30.5 years; 56.67% females; baseline mean UAS 5.2) with mean
duration of CSU of 18.9 months were enrolled. Fourteen (51.85%), 10(37.04%) and 2(7.41%) patients
became symptom-free with 20,40, and 80 mg dose of bilastine respectively whereas 1(3.70%) patient not
responding to 80 mg bilastine required cyclosporine. After 1 week of treatment, 3 patients were lost to
follow up. Bilastine was well tolerated without any serious adverse events.
Conclusion: Bilastine is effective and well tolerated in higher (up to 4 times) than normal doses in the
management of chronic spontaneous urticaria.

Keywords: Bilastine, Chronic spontaneous urticaria, Efficacy.

How to cite : Godse K, Godse G, Bilastine in higher doses in chronic spontaneous urticaria. IP Indian J Clin Exp Dermatol 2019;5(3):261-263

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.